Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, Gonzalez M, Maroto PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM. Agarwal N, et al. Among authors: arranz arija ja. Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436. Online ahead of print. Clin Cancer Res. 2024. PMID: 38512117
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
Méndez-Vidal MJ, Lázaro Quintela M, Lainez-Milagro N, Perez-Valderrama B, Suárez Rodriguez C, Arranz Arija JÁ, Peláez Fernández I, Gallardo Díaz E, Lambea Sorrosal J, González-Del-Alba A. Méndez-Vidal MJ, et al. Among authors: arranz arija ja. Clin Transl Oncol. 2023 Sep;25(9):2732-2748. doi: 10.1007/s12094-023-03276-5. Epub 2023 Aug 9. Clin Transl Oncol. 2023. PMID: 37556095 Free PMC article.
The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease.
Ortiz A, Quiroga B, Díez J, Escalada San Martín FJ, Ramirez L, Pérez Maraver M, Martínez-Berganza Asensio ML, Arranz Arija JÁ, Alvarez-Ossorio Fernández JL, Córdoba R, Brotons Muntó F, Cancelo Hidalgo MJ, Carles Reverter J, Plasencia-Rodríguez C, Carretera Gómez J, Guijarro C, Freijo Guerrero MDM, de Sequera P. Ortiz A, et al. Among authors: arranz arija ja. Nefrologia (Engl Ed). 2023 Mar-Apr;43(2):245-250. doi: 10.1016/j.nefroe.2023.06.005. Epub 2023 Jul 3. Nefrologia (Engl Ed). 2023. PMID: 37407308 Free article.
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.
Rodríguez Pérez A, Felip Font E, Chicas-Sett R, Montero-Luis Á, de Paz Arias L, González-Del-Alba A, López-Campos F, López López C, Hernando Requejo O, Conde-Moreno AJ, Arranz Arija JÁ, de Castro Carpeño J. Rodríguez Pérez A, et al. Among authors: arranz arija ja. Clin Transl Oncol. 2023 Apr;25(4):882-896. doi: 10.1007/s12094-022-03011-6. Epub 2022 Dec 16. Clin Transl Oncol. 2023. PMID: 36525231
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital.
Villanueva-Bueno C, Collado-Borrell R, Escudero-Vilaplana V, Revuelta-Herrero JL, Marzal-Alfaro MB, González-Haba E, Arranz-Arija JÁ, Osorio S, Herranz-Alonso A, Sanjurjo-Saez M. Villanueva-Bueno C, et al. Among authors: arranz arija ja. Front Public Health. 2022 Nov 4;10:978783. doi: 10.3389/fpubh.2022.978783. eCollection 2022. Front Public Health. 2022. PMID: 36407983 Free PMC article.
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C. Grande E, et al. Among authors: arranz arija ja. ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405437 Free PMC article. Clinical Trial.
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).
Valderrama BP, González-Del-Alba A, Morales-Barrera R, Peláez Fernández I, Vázquez S, Caballero Díaz C, Domènech M, Fernández Calvo O, Gómez de Liaño Lista A, Arranz Arija JÁ. Valderrama BP, et al. Among authors: arranz arija ja. Clin Transl Oncol. 2022 Apr;24(4):613-624. doi: 10.1007/s12094-022-02815-w. Epub 2022 Mar 26. Clin Transl Oncol. 2022. PMID: 35347572 Free PMC article.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
29 results